From Lab to Patient
Turning a gene therapy from a laboratory idea into an approved treatment is a long journey with many steps — and several tracks that run in parallel. Here is the whole picture, in plain language.
Scroll sideways to see the full roadmap →
Each step, explained
The same eight stages, with a little more detail on what actually happens at each one.
Discovery & target
~2–4 yrsScientists pinpoint the faulty gene, work out how it causes disease, and design the therapy — usually a healthy copy of the gene packaged inside a harmless delivery vector (AAV). First proof comes from cells and lab-grown 'mini-retinas'.
Animal proof-of-concept
~2–4 yrsThe therapy is tested in animal models — often first in mice, then in a larger animal such as a dog — to show it can preserve or restore vision and behaves safely before any human is treated.
IND-enabling studies
~1–2 yrsThe formal pre-human work: rigorous safety (toxicology) and biodistribution studies, plus manufacturing a clinical-grade batch of the vector under strict quality rules (called CMC). This is the costly stage where many programs pause to raise money.
IND application
monthsThe team submits an Investigational New Drug (IND) application asking the regulator (the FDA in the US, or a national authority elsewhere) for permission to test the therapy in people. A trial can only begin once it is cleared.
Phase 1/2 trial
~2–4 yrsThe first study in humans, in a small number of patients. The main goals are safety and finding the right dose — usually delivered by a careful surgical injection — with the first hints of whether vision improves.
Phase 3 / pivotal trial
~2–4 yrsA larger, carefully controlled study designed to prove the therapy genuinely helps, measured against a specific outcome agreed with the regulator in advance. For very rare diseases this step is sometimes adapted or combined with Phase 2.
Regulatory review
~1 yrAll the evidence — clinical results, long-term safety, and how the product is manufactured — is bundled into a large dossier (a BLA in the US, an MAA in Europe) that the regulator examines before deciding.
Approval & access
ongoingIf approved, the therapy becomes available to patients, and long-term follow-up continues to track how safe and durable it is. Access, cost and reimbursement then vary by country.
How patients join a trial
'Patient recruitment' is one of the hardest parts of a rare-disease trial, because the number of eligible people is small. For families, this is often the step they experience first-hand. Here is what it involves.
- 1
Genetic diagnosis
A genetic test must confirm a mutation in the exact gene the therapy targets. A genetic counsellor helps interpret the result.
- 2
Being found
Eligible patients are reached through disease registries, natural-history studies, patient advocacy groups, and treating clinicians.
- 3
Screening
Doctors check the trial's inclusion criteria — for example, age and whether enough living photoreceptors remain on a retinal (OCT) scan.
- 4
Informed consent
The patient and family go through the risks and what taking part involves, and give written consent before anything else.
- 5
Enrolment & dosing
The patient is enrolled, assigned to a dose or cohort, and — if it is a treatment arm — receives the therapy, then attends follow-up visits.
Registries and patient organizations are what make this possible — the more people who are genetically diagnosed and registered, the faster trials can enrol.
Can the journey be faster?
For ultra-rare diseases, regulators increasingly accept designs that reach patients sooner without lowering the safety bar. A few of the tools that can shorten the path:
- Designations like Fast Track, Breakthrough and RMAT (Regenerative Medicine Advanced Therapy) bring closer FDA guidance and can open an accelerated route to approval.
- Adaptive and intra-patient designs — where each participant is compared against their own pre-treatment baseline — replace the large randomized trial that is impractical when very few patients exist.
- Under the FDA's Rare Disease Evidence Principles (RDEP), the 'totality of evidence' is weighed together, and a marketing application can sometimes be filed on earlier (for example six-month) results, with longer-term durability supplied during review.
A 2026 example: after an FDA alignment meeting, the LCA5 gene therapy OPGx-LCA5 moved to a streamlined Phase 3 in which participants serve as their own control after a six-month run-in, with a marketing application possible on six-month data. Opus Genetics announcement
This is a simplified, general picture to help explain the process. Real programs vary widely, steps overlap and repeat, timelines shift, and many therapies never complete the journey. It is not medical or investment advice, and does not describe any specific product.